DE69332930D1 - Peptide mit breiter neoplastischer spezifizität - Google Patents

Peptide mit breiter neoplastischer spezifizität

Info

Publication number
DE69332930D1
DE69332930D1 DE69332930T DE69332930T DE69332930D1 DE 69332930 D1 DE69332930 D1 DE 69332930D1 DE 69332930 T DE69332930 T DE 69332930T DE 69332930 T DE69332930 T DE 69332930T DE 69332930 D1 DE69332930 D1 DE 69332930D1
Authority
DE
Germany
Prior art keywords
neoplastic
peptides
specificity
broad
neoplastic specificity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69332930T
Other languages
English (en)
Other versions
DE69332930T2 (de
Inventor
Couto Fernando J R Do
Roberto L Ceriani
Jerry A Peterson
Eduardo A Padlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Fund of Contra Costa
Original Assignee
Cancer Research Fund of Contra Costa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/977,696 external-priority patent/US5792852A/en
Priority claimed from US08/129,930 external-priority patent/US5804187A/en
Priority claimed from US08/134,346 external-priority patent/US6281335B1/en
Application filed by Cancer Research Fund of Contra Costa filed Critical Cancer Research Fund of Contra Costa
Application granted granted Critical
Publication of DE69332930D1 publication Critical patent/DE69332930D1/de
Publication of DE69332930T2 publication Critical patent/DE69332930T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69332930T 1992-11-16 1993-11-16 Peptide mit breiter neoplastischer spezifizität Expired - Lifetime DE69332930T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US07/977,696 US5792852A (en) 1992-11-16 1992-11-16 Polynucleotides encoding modified antibodies with human milk fat globule specificity
US129930 1993-09-30
US08/129,930 US5804187A (en) 1992-11-16 1993-09-30 Modified antibodies with human milk fat globule specificity
US08/134,346 US6281335B1 (en) 1993-10-08 1993-10-08 Hybridoma and anti-KC-4 humanized monoclonal antibody
US134346 1993-10-08
PCT/US1993/011445 WO1994011509A2 (en) 1992-11-16 1993-11-16 Peptides and anti-sense peptides with broad neoplastic specificity
US977696 2001-10-16

Publications (2)

Publication Number Publication Date
DE69332930D1 true DE69332930D1 (de) 2003-06-05
DE69332930T2 DE69332930T2 (de) 2004-02-26

Family

ID=27383951

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332930T Expired - Lifetime DE69332930T2 (de) 1992-11-16 1993-11-16 Peptide mit breiter neoplastischer spezifizität

Country Status (6)

Country Link
EP (1) EP0674710B1 (de)
JP (1) JPH09503901A (de)
AU (1) AU6396494A (de)
CA (1) CA2149529C (de)
DE (1) DE69332930T2 (de)
WO (1) WO1994011509A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
PT784684E (pt) * 1994-09-16 2007-11-23 Cancer Res Fund Of Contra Cost ''péptidos recontinantes derivados do anticorpo mc3 anti-ba46, métodos para a sua utilização e métodos de hmnanização de péptidos do anticorpo''
AUPO573697A0 (en) * 1997-03-20 1997-04-10 Prince Henry's Institute Of Medical Research Diagnosis of endometrial cancer
IL136113A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Modified antibodies with enhanced ability to elicit an anti-idiotype response
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production

Also Published As

Publication number Publication date
EP0674710B1 (de) 2003-05-02
EP0674710A1 (de) 1995-10-04
DE69332930T2 (de) 2004-02-26
WO1994011509A3 (en) 1994-07-07
WO1994011509A2 (en) 1994-05-26
AU6396494A (en) 1994-06-08
JPH09503901A (ja) 1997-04-22
CA2149529C (en) 2006-05-02
CA2149529A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
DE4393381T1 (de) Peptide
DK6893D0 (da) Peptid
NO942066L (no) Peptidderivater
DE69427370T2 (de) Neue integrinbindende peptide
DE69332485T2 (de) Immunmodulierende peptide
FI940945A (fi) Uusia isosteerisiä peptidejä
DE69315842T2 (de) Peptidverbindungen
DE68923401T2 (de) Peptide mit T-Zellen-Helfer-Wirksamkeit.
DK492788D0 (da) Peptidsynteseapparat
SE8803847A0 (sv) Neuromodulerande peptid
DE69416735T2 (de) Tertiäramino-Aluminoxan-Halide
LV10962A (lv) Jauni peptidi
DE69332930D1 (de) Peptide mit breiter neoplastischer spezifizität
FI940109A (fi) Peptidejä
DK197989A (da) Peptidanaloger
DE3778550D1 (de) Fieber- und entzuendungshemmende peptide.
DE69329145D1 (de) Anti-virale Fusionspeptide
DE3875765T2 (de) Fluor enthaltende atriale natriuretische peptide.
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
IS4382A (is) Ný peptíð með ónæmisbreytandi áhrif
KR900700503A (ko) 펩티드
MA22717A1 (fr) Peptides hemoregulateurs
NO177858C (no) Peptid
NO932237D0 (no) Lineaere peptider
FI945976A (fi) APO (a):n immunoreaktiivisia peptidejä

Legal Events

Date Code Title Description
8364 No opposition during term of opposition